Bradley Pharmaceuticals: Difference between revisions
CSV import |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 25: | Line 25: | ||
[[Category:Companies listed on the New York Stock Exchange]] | [[Category:Companies listed on the New York Stock Exchange]] | ||
{{pharma-company-stub}} | {{pharma-company-stub}} | ||
<gallery> | |||
File:Bradley_Pharmaceuticals_logo.jpg|Logo of Bradley Pharmaceuticals | |||
</gallery> | |||
Latest revision as of 19:11, 16 March 2025
Bradley Pharmaceuticals was a pharmaceutical company based in the United States. It was founded in 1985 by Daniel Glassman, a former pharmaceutical sales representative. The company was listed on the New York Stock Exchange under the ticker symbol "BDY". Bradley Pharmaceuticals primarily focused on the development and marketing of dermatology and gastroenterology products.
History[edit]
Bradley Pharmaceuticals was established in 1985 by Daniel Glassman. The company started with a focus on niche therapeutic markets, particularly dermatology and gastroenterology. Over the years, Bradley Pharmaceuticals expanded its product portfolio through a combination of internal development and acquisitions.
In 2000, Bradley Pharmaceuticals acquired Doak Dermatologics, a company specializing in dermatology products. This acquisition significantly expanded Bradley's dermatology product line.
In 2005, Bradley Pharmaceuticals acquired A. Aarons Inc., a company that specialized in generic prescription pharmaceuticals. This acquisition allowed Bradley to expand into the generic pharmaceutical market.
In 2008, Bradley Pharmaceuticals was acquired by Nycomed, a Swiss pharmaceutical company. The acquisition was valued at approximately $346 million.
Products[edit]
Bradley Pharmaceuticals developed and marketed a wide range of products, primarily in the fields of dermatology and gastroenterology. Some of their notable products included Zoderm, a prescription acne treatment, and AnaMantle, a hemorrhoid treatment.
Legacy[edit]
Bradley Pharmaceuticals left a significant impact on the pharmaceutical industry. The company's focus on niche markets allowed it to develop and market products that addressed specific patient needs. This strategy proved successful, as evidenced by the company's growth and eventual acquisition by Nycomed.
See also[edit]
This article is a pharmacology-related stub. You can help WikiMD by expanding it!
-
Logo of Bradley Pharmaceuticals
